A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts

Anesthesia and Analgesia

Volumn 102, Issue 6, 2006, Pages 1646-1652

  Zausig, York A ^a   Stowe, David F ^b   Zink, Wolfgang ^b   Grube, Christoph ^b   Martin, Eike ^b   Graf, Bernhard M ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; COROTROP; ENOXIMONE; MILRINONE; PHOSPHODIESTERASE III INHIBITOR;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR AUTOREGULATION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GUINEA PIG; HEART ELECTROPHYSIOLOGY; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE METABOLISM; HEART MUSCLE RELAXATION; HEART RATE; INOTROPISM; ISOLATED HEART; METABOLIC RATE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; VASODILATATION;

EID: 33744462053     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000216290.74626.27     Document Type: Article

References (25)

1. Movsesian MA. PDE3 cyclic nucleotide phosphodiesterases and the compartmentation of cyclic nucleotide-mediated signalling in cardiac myocytes. Basic Res Cardiol 2002;97:I/83-90.
2. Rathmell JP, Prielipp RC, Butterworth JF, et al. A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery. Anesth Analg 1998;86:683-90.
3. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
4. Booker PD, Gibbons S, Stewart JI, et al. Enoximone pharmacokinetics in infants. Br J Anaesth 2000;85:205-10.
5. Upadya S, Lee FA, Saldarriaga C, et al. Home continuous positive inotropic infusion as a bridge to cardiac transplantation in patients with end-stage heart failure. J Heart Lung Transplant 2004;23:466-72.
6. Graf BM, Fischer B, Stowe DF, et al. Synthetic 8-ornithinevasopressin, a clinically used vasoconstrictor, causes cardiac effects mainly via changes in coronary flow. Acta Anaesthesiol Scand 1997;41:414-21.
7. Rooney RT, Stowe DF, Marijic J, et al. Amrinone reverses cardiac depression and augments coronary vasodilation with isoflurane in the isolated heart. Anesthesiology 1991;74:559-67.
8. Vernon MW, Heel RC, Brogden RN. Enoximone: a review of its pharmacological properties and therapeutic potential. Drugs 1991;42:997-1017.
9. Ward A, Brogden RN, Heel RC, et al. Amrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1983;26:468-502.
10. Young RA, Ward A. Milrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1988;36: 158-92.
11. Onuaguluchi G, Tanz RD, McCawley E. Electrocardiographic changes induced by amrinone in the isolated perfused guinea-pig Langendorff heart preparation. Arch Int Pharmacodyn Ther 1983;264:263-73.
12. Chan KY, Ohlweiler DF, Lang JF, Okerholm RA. Simultaneous analysis of a new cardiotonic agent, MDL 17,043, and its major sulfoxide metabolite in plasma by high-performance liquid chromatography. J Chromatogr 1984;306:249-56.
13. Himmel HM, Schappert T, Ravens U. Combined effects of volatile anesthetics and phosphodiesterase inhibitors on contractile performance in guinea pig hearts. Anesth Analg 1991;73:76-82.
14. Joseph G, Zhao Y, Klaus W. Pharmacologic action profile of crataegus extract in comparison to epinephrine, amrinone, milrinone and digoxin in the isolated perfused guinea pig heart [in German]. Drug Res. [Arzneimittelforschung] 1995;45:1261-5.
15. Chevalier B, Mouas C, Mansier P, et al. Screening of inotropic drugs on isolated rat and guinea pig hearts. J Pharmacol Methods 1987;17:313-26.
16. Tanigawa T, Yano M, Kohno M, et al. Mechanism of preserved positive lusitropy by cAMP-dependent drugs in heart failure. Am J Physiol Heart Circ Physiol 2000;278:H313-20.
17. Lowes BD, Higginbotham M, Petrovich L, et al. Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol 2000;36:501-8.
18. Robertson DW, Boyd DB. Structural requirements for potent and selective inhibition of low-Km, cyclic-AMP-specific phosphodiesterases. Adv Second Messenger Phosphoprotein Res 1992;25:321-40.
19. Rapundalo ST, Grupp I, Grupp G, et al. Myocardial actions of milrinone characterization of its mechanism of action. Circulation 1986;73:III134-44.
20. Pagel PS, Hettrick DA, Warltier DC. Amrinone enhances myocardial contractility and improves left ventricular diastolic function in conscious and anesthetized chronically instrumented dogs. Anesthesiology 1993;79:753-65.
21. Dole WP. Autoregulation of the coronary circulation. Prog Cardiovasc Dis 1987;29:293-323.
22. Baim DS. Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow. Am J Cardiol 1989;63:23A-6.
23. Gregg DE. Relationship between coronary flow and metabolic changes. Cardiology 1971;56:291-301.
24. Viquerat CE, Kereiakes D, Morris DL, et al. Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure. J Am Coll Cardiol 1985;5:326-32.
25. Binah O, Rosen MR. Developmental changes in the interactions of amrinone and ouabain in canine ventricular muscle. Dev Pharmacol Ther 1983;6:333-46.